The National Institute for Clinical Excellence (NICE) has recommended eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpurai (ITP).
The watchdog has issued draft guidance saying the drug, produced by GlaxoSmithKline under the name Revolade, should be used for adults who have had their spleen removed and who have shown resistance to other treatments including corticosteroidsiii and immunoglobulinsiv.
Patients who have not been given a splenectomy due to the risks of surgery may also be given eltrombopag if the manufacturer agrees to supply it with the discount which has been agreed as part of the patient access scheme.
The original guidance, which was published more than two years ago, was looked at again by NICE after the manufacturer produced a patient access scheme. And the watchdog ruled that eltrombopag was an effective treatment for patients with chronic ITP as well as romiplostim, which was recommended in NICE guidance last year.
NICE’s health technology evaluation centre director Dr Carole Longson said those with ITP were in constant danger of suffering from bleeding and bruising, which had a negative impact on their daily lives. She said the draft guidance for eltrombopag was now the subject of a consultation and registered stakeholders could now express their views on the NICE website.
The final guidance is expected to be published next May.